Background: Detailed catalog of lung cancer-associated gene mutations provides valuable information for lung cancer diagnosis and treatment. In China, there has never been a wide-ranging study cataloging lung cancer-associated gene mutations. This study aims to reveal a comprehensive catalog of lung cancer gene mutations in China, focusing on EGFR, ALK, KRAS, HER2, PIK3CA, MET, BRAF, HRAS, and CTNNB1 as major targets. Additionally, we also aim to correlate smoking history, gender, and age distribution and pathological types with various types of gene mutations.

Patients and Methods: A retrospective data acquisition was conducted spanning 6 years (2013–2018) among all patients who underwent lung cancer surgeries not bronchial or percutaneous lung biopsy at three major tertiary hospitals. Finally, we identified 1,729 patients who matched our inclusion criteria.

Results: 1,081 patients (62.49%) harbored EGFR mutation. ALK (n = 201, 11.62%), CTNNB1 (n = 28, 1.62%), BRAF (n = 31, 1.79%), PIK3CA (n = 51, 2.95%), MET (n = 14, 0.81%), HER2 (n = 47, 2.72%), HRAS (n = 3, 0.17%), and other genes (n = 232, 13.4%). Females expressed 55.38% vs. males 44.62% mutations. Among subjects with known smoking histories, 32.82% smokers, 67.15% non-smokers were observed. Generally, 51.80% patients were above 60 years vs. 48.20% in younger patients. Pathological types found includes LUADs 71.11%, SQCCs 1.68%, ASC 0.75%, LCC 0.58%, SCC 0.35%, ACC 0.17%, and SC 0.06%, unclear 25.19%.

Conclusion: We offer a detailed catalog of the distribution of lung cancer mutations. Showing how gender, smoking history, age, and pathological types are significantly related to the prevalence of lung cancer in China.

Keywords: lung cancer, China, gene mutation, aging, tobacco smoking, pathology
INTRODUCTION

Lung cancer is the most common cancer and the leading cause of cancer-related mortality around the world despite extensive concerted study. In China, nearly 3,804,000 (2,114,000 men, 1,690,000 women) lung cancer cases were diagnosed in 2014, which is the equivalent of more than 10,422 cases diagnosed each day (1). High prevalence of driver gene mutations and fusions in EGFR, ALK, RET, ROS1, and KRAS in lung LUAD patients, have been observed in China (2, 3). Especially, point mutations L858R and E746_A750del comprised nearly 90% of all EGFR mutations in NSCLC (4). Notably, non-smoker East Asian women are more likely to develop LUAD and exhibit a higher incidence of EGFR mutation and a lower KRAS mutation frequency (5). Smoking is the leading cause of lung cancer, as <20% of smokers develop this deadly disease in their lifetime but non-smokers with increased risk of lung cancer usually have a family history of cancer. More women suffer from lung cancer. In comparison to the male patients they are younger and more likely never-smokers (6). Age is associated with cancer development due to biologic factors that include DNA damage over time and shortening telomeres (7). Accordingly, the median age of lung cancer diagnosis is 70 years for both men and women. Approximately 53% of cases occur in individuals 55 to 74 years old and 37% occur over 75 years old (8).

In this study we attempted to reveal a detailed catalog of gene mutations in cancer patients within China, detailing EGFR, ALK, KRAS, HER2, PIK3CA, MET, BRAF, Hras, CTNNB1, and other genes concerning its relationship with gender, age, smoking history, and pathological presentations.

METHODS

A retrospective data acquisition was conducted spanning 6 years (2013–2018) among all patients who attended lung cancer out-patient consultations and underwent lung cancer-related surgeries at three major tertiary hospitals. The data were collected from hospital medical records which comprised clinical medical history, radiology reports, pathology reports, and for some patients whose information was incomplete or incoherent, follow up phone calls were made to ascertain or verify them.

Statistics

Statistical analyses such as p-value calculations were conducted using regression analysis by finding the $R^2$ values. The p-value for each independent variable was used to test the null hypothesis that the variable has no correlation with the dependent variable. An alpha of 0.05 is used as the cutoff for significance. If the $p < 0.05$, we reject the null hypothesis that there’s no difference between the means and conclude that a significant difference does exist. If the p-value is larger than 0.05, we cannot conclude that a significant difference exists. Data analysis was conducted using Microsoft Excel for iMac, Version 16.30.

Inclusion and Ethical Considerations

The inclusion criteria were all cases with a component of Non-Small Cell Lung cancer and/or adenocarcinomatous differentiation or those in which a pulmonary carcinoma or adenocarcinomatous component could not be excluded, verified by a pathologist before being included in the study. Approval from the Institutional Ethical Committee was obtained prior to data collection during data collection from all three institutions, no other clinicopathologic data were collected for this analysis except those necessary for this study.

FINDINGS ANALYSIS

In our study, all three hospitals had data on the following genetic mutations EGFR, ALK, KRAS, HER2, PIK3CA, MET, BRAF, Hras, CTNNB1. However, data about other mutations were collected from one individual hospital. It was observed that the preponderance of genetic modifications was not evenly distributed. EGFR, KRAS, ALK, BRAF, HER2, PIK3CA, related mutations occurred in higher frequency, percentage population of patients can be found in Figure 1 and, gene localization can be found in Figure 2.

Detected Genetic Mutation Loci

In this study, a total of 1,729 test reports were analyzed, including 1,081 (62.49%) EGFR mutation carriers. EGFR mutations were classified in relation to the locations of point mutations. Exon 18, Exon 19, Exon 20 and Exon 21 mutations were found in 32 (2.61%), 390 (31.86%), 34 (2.78%), and 548 (44.77%) cases, respectively. However, there were cases of multiplicity where EGFR activity was observed in multiple exons such as Exon 18 and 19, 18 and 20, 18 and 21, 19 and 20, 19 and 21, 20 and 21. Details can be found in Figure 1B. Also, in our cohort, 11.62% of patients were found to bear KRAS mutations and 32.8% of them were found to exhibit mutations at the p.G12C position. It was noted that the least occurring mutations included p.Y40F, p.Q61R, p.Q61L, p.Q61H, p.L19F as at the p.G12C position. It was noted that the least occurring mutations included p.Y40F, p.Q61R, p.Q61L, p.Q61H, p.L19F as illustrated in Figure 2. ALK mutations were detected as follows: 42 (2.43%) EML4-ALK. Gene localization revealed $n = 27$ as fusion genes, while others were identified on Exons 20 ($n = 15$), Exon 13 ($n = 7$), Exon 2 ($n = 3$), Exon 6 ($n = 3$), and Exon 9 ($n = 1$). The BRAF gene was observed to comprise 1.79% ($n = 31$) of lung cancer-associated gene mutations in our cohort and 64.52% of mutation cases were male and mainly comprised of p.V600E at Exon 15. Furthermore, non-p.V600E mutations ($n = 11$, 34.37%) occurred between Exon 15 and Exon 11 as seen in Figure 3. PIK3CA prevalence in our sample population was 2.95% just above the range of 1.5–2.6% (9) and Exon 9 prevalence was previously reported as 78.6% (9) contrary to our findings of 33.33% patients affected at Exon 9, in our study population. Exon 10 affection was most observed, recorded at 35.29%. Gene localizations are shown in Figure 3 with p.E542K and p.E545K accounting for the majority of occurrences. Among patients with MET anomalies, $n = 7$ (64.3%) were METamp, other MET modifications recorded equal distribution among our patients as follows; $n = 1$ MET c.3736G>C p.D1246H, an amino acid missense substitution mutation on position

Abbreviations: LUAD, Lung Adenocarcinoma; ACC, Adenoid cystic carcinoma; ASC, Adenosquamous Carcinoma; LCC, Large Cell Carcinoma; SCC, Small Cell Carcinoma; SC, Sarcomatoid Carcinoma; SQCC, Squamous Cell Carcinoma.
1,246, \( n = 1 \) c.3082G>C, p.D1028H, an amino acid substitution mutation at position 1,028, \( n = 1 \) c.2942-24_2942-1del24, \( n = 1 \) c.3075_3082+4del12, \( n = 1 \) c.3028G and \( n = 1 \) c.G3028C. Forty-seven \( (n = 47) \) HER2 mutations were detected. Among the most significant mutations are: \( n = 4 \) (8.51%) HER2 gene amplification, \( n = 14 \) (29.79%) p.A775_G776insYVMA in-frame insertion mutations, \( n = 10 \) (21.28%) p.Ala771_Met774dup.

Gender Associations With Detected Mutations
Gender associations among all examined patients revealed \( n = 771 \) (44.62%) males and \( n = 957 \) (55.38%) females, as seen in Table 1.

Genetic anomalies with predominant female involvement include EGFR females \( n = 685 \) (63.43%), ALK \( n = 24 \) (57.14%), HER2 \( n = 30 \) (63.83%), MET \( n = 8 \) (57.14%) while genetic activity found to involve more males are as follows: KRAS \( n = 143 \) (71.14%), BRAF \( n = 20 \) (64.52%), PIK3CA \( n = 28 \) (54.90%), HRAS \( n = 2 \) (66.67), CTNNB1 \( n = 16 \) (57.14%) and other genes as shown in Figure 4.

Smoking History Interdependence With Mutations
Smoking histories of our cohort were also elucidated. It revealed that within our study population, there were more non-smokers (67.15%) than smokers (32.82%). However, among the male population with known smoking histories, \( n = 381 \) (64.52%) were smokers and \( n = 254 \) (39.35%) were non-smokers, while among the female population, \( n = 111 \) (66.67) were known smokers and \( n = 755 \) (78.90%) were non-smokers. There were other patients whose smoking histories could not be ascertained at the time of this study \( n = 228 \) (13.11%). In our study, genetic mutations including EGFR, KRAS, ALK, BRAF, PIK3CA, HRAS, CTNNB1, HER2, and MET were predominant among male smokers, while on the other hand female non-smokers were shown to be more susceptible to all studied lung cancer-associated gene mutations. Details of gender correlation with smoking histories can be found in Figure 5.

Age Correlation With Mutation
Age distribution among our study patients showed under-60 patients (48.20%) and over-60 patients (51.80%). Furthermore, among the population <60 years of age, more females (57.91%) were found to have a mutation, the same for females above 60 years of age (53.25%). Details showing the correlation between specific gene mutations, age, and patient’s gender can be found in Figure 6.

Pathological Presentation of Mutation
It was observed that majority of patients presented with LUAD lesions \( n = 1231 \) (71.11%), SQCC \( n = 29 \) (1.68%), ASC \( n = 13 \) (0.75%), LCC \( n = 10 \) (0.58%), SCC \( n = 6 \) (0.35%), ACC \( n = 3 \) (0.17%), sarcomatous carcinoma \( n = 1 \) (0.06%) and there were \( n = 436 \) (25.19%) patients whose pathological types could not be ascertained at the time of this study.

LUAD lesions were most rampant among our cohort, where EGFR \( n = 847 \) (78.83%), ALK \( n = 25 \) (59.52%), KRAS \( n = 110 \) (54.73%), HER2 \( n = 35 \) (74.47%), MET \( n = 12 \) (85.71%), BRAF \( n = 17 \) (53.13%), PIK3CA \( n = 30 \) (58.82%), and CTNNB1 \( n = 16 \) (57.14%) all had predominantly adenocarcinomatous presentations while a single patient harboring HRAS gene mutation presented with SQCC. Details in Table 2.

---

**FIGURE 1** (A) A pie chart representing the percentage distribution of all studied genetic mutations among our study population. (B) Outlines the percentage duplication and triplication of EGFR mutations among patients in our cohort on Exons 18, 19, 20, and 2. For a detailed breakdown of mutation counts.
SQCCs, LCCs, and ACCs were found to be more common among females while ASCs, LCCs, SCCs, and SCs were predominant among males. Details in Table 3. On-the-other-hand, LUAD, SQCC, and LCC occurred frequently among non-smokers, while ASC, SCC, ACC, and SCs occurred mostly among smokers as seen in Table 3.

DISCUSSION

The establishment of solid evidence of genetic predisposition to the risk of lung cancer has a potential clinical utility for not only stratification of the population, but also primary prevention. Our objective in this study was to elucidate, comprehend and interpret the association of various genetic mutations using an extensive exploration of organized metadata concerning gender and smoking habits and age with information gathered from three Chinese hospitals.

Distribution of Mutations

According to Greulich H. et al. in the United States, somatic alterations of 5 lung adenocarcinoma oncogenes, KRAS, EGFR, ALK, ERBB2(HER2), and BRAF, are interestingly mutually exclusive and are represented in over 50% of lung adenocarcinomas (10) (Figure 1). Other studies also elaborate on the dominance of EGFR mutations among NSCLC patients (11, 12). On the other hand, in China, the same group of 5
oncogenes amounted to 81% of lung cancers, which is largely attributable to the high frequency of EGFR mutations including multiple occurrences of the EGFR mutations as seen in China (Table 4), vs. to non-Asian populations (13, 14).

Also according to the AACR project GENIE consortium database, EGFR is mutated in 22.17%, ALK is mutated in 5.05%, BRAF is mutated in 5.34%, ERBB2 (HER2) is mutated in 4.12%, HRAS is mutated in 0.43%, KRAS is mutated in 29.7%, MET is mutated in 5.18%, NRAS is mutated in 1.14% and PIK3CA is mutated in 7.47% of non-small cell lung carcinoma patients. In comparison to our results seen in Figure 1, there is a considerable departure, with one of the obvious causes being ethnic variations in genetic makeup (15).

The results of this study reflected the tremendous data available for the study of mutations in China. This is mostly due to the widespread availability of testing centers at various hospitals across the country which has resulted in early detection of genetic mutation associated with non-small cell lung cancer in the affected population.

Our study further confirmed that Asians who harbor NSCLC have similar genetic components (16–19), as also demonstrated in a study conducted among Korean patients (14). In France,
TABLE 1 | Illustrates the correlation between the individual genetic mutations, the gender distribution of each mutant gene, smoking history among or lack thereof among patients, and the age distribution.

| GENE | n (%) | Female (%) | Male (%) | n* | p-value | u | Non-smoker (%) | Smoker (%) | n** | p-value | u* | <= 60(%) | >60(%) | n*** | p-value | u* |
|------|-------|------------|----------|-----|---------|---|----------------|------------|-----|---------|----|--------|-------|------|--------|----|
| EGFR | 1,081 (62.49%) | 685 (63.43%) | 396 (36.57%) | 1,080 | < 0.0001 | 1 | 774 (74.71%) | 262 (25.29%) | 1,036 | < 0.0001 | 45 (4.16%) | 526 (48.79%) | 552 (51.21%) | 1,078 | 0.0207 | 3 |
| ALK  | 42 (2.43%) | 24 (57.14%) | 18 (42.86%) | 42 | 0 | 21 (70.00%) | 9 (30.00%) | 30 | 0.0004 | 12 (28.57%) | 33 (78.57%) | 9 (21.43%) | 42 | 0.0854 |
| KRAS | 201 (11.62%) | 58 (28.68%) | 143 (71.14%) | 201 | < 0.0001 | 144 (43.21%) | 60 (57.49%) | 104 | < 0.0001 | 97 (48.26%) | 88 (43.78%) | 113 (56.22%) | 201 | 0.7718 |
| HER2 | 47 (2.72%) | 30 (63.83%) | 17 (36.17%) | 47 | < 0.0001 | 30 (78.95%) | 8 (21.05%) | 38 | < 0.0001 | 9 (19.15%) | 28 (62.22%) | 17 (37.78%) | 45 | 0.9234 |
| MET  | 14 (0.81%) | 8 (57.14%) | 6 (42.86%) | 14 | < 0.0001 | 1 (78.57%) | 3 (21.43%) | 14 | 0.0001 | 0 (0.00%) | 4 (28.57%) | 10 (71.43%) | 14 | 0.4071 |
| HRAS | 3 (0.17%) | 1 (33.33%) | 2 (66.67%) | 3 | 0.4226 | 1 (33.33%) | 2 (66.67%) | 3 | 0.4226 | 0 (0.00%) | 0 (0.00%) | 3 (100.00%) | 3 | – |
| BRAF | 31 (1.79%) | 11 (35.48%) | 20 (64.52%) | 31 | < 0.0001 | 9 (78.95%) | 3 (21.05%) | 13 | < 0.0001 | 10 (76.92%) | 42 (57.14%) | 31 (42.86%) | 32 | 0.7108 |
| PIK3CA | 51 (2.95%) | 23 (45.10%) | 28 (54.90%) | 51 | < 0.0001 | 18 (35.29%) | 13 (64.71%) | 31 | < 0.0001 | 13 (26.08%) | 30 (58.82%) | 20 (42.31%) | 31 | 0.0001 |
| CTNNB1 | 28 (1.62%) | 12 (42.86%) | 16 (57.14%) | 28 | < 0.0001 | 11 (46.43%) | 17 (53.57%) | 26 | 0.0001 | 10 (38.46%) | 14 (53.85%) | 18 (60.71%) | 28 | 0.4983 |
| OTHERS | 232 (13.41%) | 105 (45.45%) | 126 (54.55%) | 231 | < 0.0001 | 87 (37.50%) | 143 (62.50%) | 200 | < 0.0001 | 31 (15.50%) | 106 (53.00%) | 126 (58.00%) | 231 | 0.2631 |

Grand Total | 1,730 (100%) | 957 (55.38%) | 773 (44.62%) | 2 | 1,008 (67.15%) | 493 (32.82%) | 228 (13.11%) | 831 (48.20%) | 894 (51.80%) | 5 | – |

All total percentages were calculated from patients with available data such as gender, smoking history and age. n**-Total number of smokers and non-smokers per gender group with recorded smoking history. n***-Total number of under 60 and over 60 patients per gender group with recorded age. u* Unknown or unclear data at the time of the study. u (%) The percentage shown are the percentage of the total number of tumors n per gene group who have no smoking history data. p-value; an alpha of 0.05 is used as the cutoff for significance. If the p < 0.05, we reject the null hypothesis that there’s no difference between the means and conclude that a significant difference does exist. If the p-value is larger than 0.05, we cannot conclude that a significant difference exists.

Smoking History

Cigarette smoking is by far the leading cause of lung cancer. In Japan, as shown in a study conducted on NSCLC patients, 0.8% of the population had mutations (4, 29). In contrast to previous enumerated genetic aberrations, we have seen that MET genetic activity in our cohort falls quite small. Notably, MET mutations were found predominantly in male smokers (14). However, in our study, 1.79% of EGFR mutations (4, 29).

In previous studies, we have seen that MET genetic activity in our cohort falls quite small. Notably, MET mutations were found predominantly in male smokers (14). However, in our study, 1.79% of EGFR mutations (4, 29). In Japan, as shown in a study conducted on NSCLC patients, 0.8% of the population had mutations (4, 29). In contrast to previous enumerated genetic aberrations, we have seen that MET genetic activity in our cohort falls quite small. Notably, MET mutations were found predominantly in male smokers (14). However, in our study, 1.79% of EGFR mutations (4, 29). In previous studies, we have seen that MET genetic activity in our cohort falls quite small. Notably, MET mutations were found predominantly in male smokers (14). However, in our study, 1.79% of EGFR mutations (4, 29). In previous studies, we have seen that MET genetic activity in our cohort falls quite small. Notably, MET mutations were found predominantly in male smokers (14). However, in our study, 1.79% of EGFR mutations (4, 29).
MET mutations have recently been shown to occur in 3 to 4% of NSCLC adenocarcinomas, 2% of squamous cell carcinomas, and 1 to 8% of other subtypes of lung cancers (27). Noteworthy, it's more common among non-smokers (30), indicating 55.7% MET mutations among non-smokers vs. 61.11% non-smokers who were found to harbor MET mutations in our cohort.
HER2 mutations were observed in 2.72% of NSCLCs, particularly in younger patients, and those with no history of smoking which is within the 2–4% range seen in Japan (6, 31). Elsewhere in China, it was also found that 1.9% of NSCLC patients had HER2 activity among never smokers who happen to be no more than 60 years old (32).

Despite the rarity of the CTNNB1 mutations, we were able to find its occurrence in 1.62% of our study population, which is quite similar to 1.5% obtained in Germany (10). It is noteworthy that genetic alteration of the β-catenin gene (CTNNB1) in human lung cancer was first elaborately reported when four alterations were found in Exon 3 (7). In our study population, all 28 patients had mutations on Exon 3 which is the target region of mutation for stabilizing β-catenin. More non-smokers 39.2% bore CTNNB1 mutations compared to smokers 21.42%. However, for more accurate study, it’s important to clearly isolate never smokers from previous smokers, light smokers, and current smokers in order to have unclouded scrutiny of patients’ interconnection with genetic mutability.

**Gender Interrelationship**

A study of 50-year trends in smoking-related mortality in the USA found that males had higher relative risks of smoking-related lung cancer mortality were higher compared to females (33). In contrast, a recent study in Korea suggested that gender differences in the impact of smoking on lung cancer risk exist and differ by histological subtype (34). Analyses of a large primary care database in the UK showed that moderate and heavy smoking more strongly increases the risks of lung cancer in women than in men (35).

It was previously reported that subject to availability of data in regions were studies were carried out, EGFR mutation frequency in patients with NSCLC/ LUAD was higher in women compared with men: Europe, 22 vs. 9%; Asia-Pacific 60 vs. 37%; Indian subcontinent, 31 vs. 23%; Africa, 48 vs. 8%; and North America 28 vs. 19% (36). In our study, EGFR patients also demonstrated a larger female to male ratio where we have 63.37% females vs. 36.54% males. Among our KRAS affected study population, we found that more males were associated with KRAS mutations to the tune of 71.14% male and 28.86% females which corresponds...
TABLE 2 | Illustrates the correlation between the individual genetic mutations, and various pathological types observed in our study population.

| GENE     | Adenocarcinoma (%) | Unclear (%) | Squamous cell carcinoma (%) | Adenosquamous carcinoma (%) | Large Cell carcinoma (%) | Small Cell carcinoma (%) | Adenoid cystic carcinoma (%) | Sarcomatous carcinoma (%) | Grand total |
|----------|---------------------|-------------|-----------------------------|-----------------------------|--------------------------|--------------------------|-----------------------------|---------------------------|-------------|
| EGFR     | 847 (78.35%)        | 217 (20.07%) | 5 (0.46%)                   | 9 (0.83%)                   | 0 (0.00%)                | 3 (0.28%)                | 0 (0.00%)                   | 0 (0.00%)                 | 1,081       |
| ALK      | 25 (59.52%)         | 16 (38.10%)  | 0 (0.00%)                   | 0 (0.00%)                   | 0 (0.00%)                | 0 (0.00%)                | 1 (2.38%)                   | 0 (0.00%)                 | 42          |
| KRAS     | 110 (54.73%)        | 83 (41.29%)  | 5 (2.49%)                   | 1 (0.50%)                   | 2 (1.00%)                | 0 (0.00%)                | 0 (0.00%)                   | 0 (0.00%)                 | 201         |
| HER2     | 35 (74.47%)         | 12 (25.53%)  | 0 (0.00%)                   | 0 (0.00%)                   | 0 (0.00%)                | 0 (0.00%)                | 0 (0.00%)                   | 0 (0.00%)                 | 47          |
| MET      | 12 (85.71%)         | 2 (14.29%)   | 0 (0.00%)                   | 0 (0.00%)                   | 0 (0.00%)                | 0 (0.00%)                | 0 (0.00%)                   | 0 (0.00%)                 | 14          |
| HRAS     | 0 (0.00%)           | 2 (86.67%)   | 1 (33.33%)                  | 0 (0.00%)                   | 0 (0.00%)                | 0 (0.00%)                | 0 (0.00%)                   | 0 (0.00%)                 | 3           |
| BRAF     | 17 (53.13%)         | 14 (43.75%)  | 0 (0.00%)                   | 0 (0.00%)                   | 0 (0.00%)                | 0 (0.00%)                | 0 (0.00%)                   | 0 (0.00%)                 | 31          |
| PIK3CA   | 30 (58.82%)         | 14 (27.45%)  | 5 (9.80%)                   | 0 (0.00%)                   | 0 (0.00%)                | 1 (1.96%)                | 1 (1.96%)                   | 0 (0.00%)                 | 51          |
| CTNNB1   | 16 (57.14%)         | 11 (39.29%)  | 1 (3.57%)                   | 0 (0.00%)                   | 0 (0.00%)                | 0 (0.00%)                | 0 (0.00%)                   | 0 (0.00%)                 | 28          |
| OTHERS   | 139 (59.91%)        | 65 (28.02%)  | 12 (5.17%)                  | 3 (1.29%)                   | 8 (3.45%)                | 2 (0.86%)                | 1 (0.43%)                   | 1 (0.43%)                 | 232         |
| TOTAL    | 1,231 (71.11%)      | 436 (25.19%) | 29 (1.68%)                  | 13 (0.75%)                  | 10 (0.68%)               | 6 (0.35%)                | 3 (0.17%)                   | 1 (0.06%)                 | 1,728       |

TABLE 3 | Illustrates the distribution of the pathologic presentations between gender and smoking histories.

| %      | f (gender) | Gender | Pathologic type | Smoking history | f (smoking) | %    |
|--------|------------|--------|-----------------|-----------------|-------------|------|
| 59.46% | 732        | Female | Adenocarcinoma  | Non-smoker      | 780         | 63.36%|
| 40.45% | 498        | Male   | Squamous cell carcinoma | Non-smoker | 361 | 29.33%|
| 51.72% | 15         | Female | Adenosquamous carcinoma | Non-smoker | 98 | 7.31%|
| 48.28% | 14         | Male   | Small cell carcinoma | Non-smoker | 7 | 48.28%|
| 38.46% | 5          | Female | Adenosquamous carcinoma | Non-smoker | 4 | 27.59%|
| 61.54% | 8          | Male   | Adenocarcinoma   | Non-smoker      | 8 | 30.77%|
| 10.00% | 1          | Female | Large cell carcinoma | Non-smoker | 6 | 6.67%|
| 90.00% | 9          | Male   | Squamous cell carcinoma | Non-smoker | 2 | 20.00%|
| 16.67% | 1          | Female | Small cell carcinoma | Non-smoker | 2 | 66.67%|
| 83.33% | 5          | Male   | Adenoid cystic carcinoma | Non-smoker | 4 | 48.28%|
| 66.67% | 2          | Female | Adenoid cystic carcinoma | Non-smoker | 0 | 0.00%|
| 33.33% | 1          | Male   | Non-smoker       | 3 | 100.00%|
| 0      | 0          | Female | Sarcomatoid carcinoma | Non-smoker | 0 | 0.00%|
| 100%   | 1          | Male   | Smoker           | 1 | 100.00%|
| 46.10% | 201        | Female | Unclear         | 111 | 25.46%|
| 53.90% | 234        | Male   | Non-smoker      | 197 | 45.18%|
| 1      | 1          | Unknown | Non-smoker | 128 | 29.36%|
| 1,729  |            |        |                 |                 |             |      |

to an earlier finding among Turkish patients where (58%) male and (42%) female were identified among KRAS patients (15). RAS oncogene has three known isoforms as Harvey-RAS (HRAS), Kirsten-RAS (KRAS) and Neuroblastoma-RAS (NRAS). HRAS mutations are observed very rarely in lung cancers (<1%) (37). As seen in our cohort, only 0.1% of patients had HRAS mutation, both of whom were male smokers. Little is known about this gene and its lung cancer affectation.

Correlation With Aging
Cancer is a disease associated with aging—the majority of cancer diagnoses and deaths occur in people older than 65 years (38). Of particular interest is the finding that Asian women with the EGFR mutation developed adenocarcinoma at an earlier age than other lung cancer patients (5, 39). In our study, EGFR anomalies were detected in young patients ranging from 18 to 87 years, even though the median age was about 60 years (2). HER2
alterations were also spotted among younger patients with age ranging from 22 to 96 years. Of note is an 18-year-old male patient who was the youngest patient with ALK mutation in our study group. Numerous explanations have been offered as to the biologic connection between cancer and aging, including extended exposure to carcinogens (13), increased susceptibility to oxidative stress (40), immune dysregulation (41). While these explanations for the link between cancer and aging are plausible, they do not pinpoint the reason why one older adult is more susceptible to cancer than another. Furthermore, the association between cancer and aging is complex. It however appears that age independently associates with EGFR mutation among lung cancer (42).

### Pathological Presentations

Lung cancers are traditionally divided into non–small cell carcinoma (NSCC) and SCC (small cell lung carcinoma, SCLC), with the former accounting for 80% of the cases and the latter accounting for the remaining 20%. Lung cancer can be diagnosed pathologically either by a histologic or cytologic approach (43), of which in our study the histologic approach was used. There exists strong disparities between lung LUAD in the Europeans vs. East Asians which could mainly be due to the disparity in smoking habits between both populations with the majority of the driver genes being EGFR and KRAS (20). In a Korean study using data from the Korea Central Cancer Registry (2), it was reported that a higher risk for having ever smoked was observed for squamous-cell and small-cell carcinoma in both men and women. However,

---

**TABLE 4** | Outlines the multiplicity of distribution of EGFR mutations among patients in our cohort on Exons 18, 19, 20, and 21.

| EGFR Exon | Mutation Counts | Percentage (%) |
|--------|----------------|----------------|
| 18     | 32             | 2.61%          |
| 19     | 390            | 31.86%         |
| 20     | 34             | 2.78%          |
| 21     | 548            | 44.77%         |
| 18/19  | 1              | 0.08%          |
| 18/20  | 16             | 1.31%          |
| 18/20/21 | 2        | 0.16%          |
| 18/21  | 5              | 0.41%          |
| 19/20  | 16             | 1.31%          |
| 19/21  | 3              | 0.25%          |
| 20/21  | 28             | 2.29%          |
| Insertion mutation | 5       | 0.41%          |
| Unclear Loci* | 144    | 11.76%         |

**Total Count** | 1,224

*Unclear loci indicates patients whose gene analysis detected an EGFR mutation but which specific Exonal position remains unclear. **Total count refers to the total count of occurrences of mutations including the duplicates and triplicates among 1,081 recorded EGFR patients.

---

**FIGURE 7** | Alluvial diagram showing the flow distribution of genetic activity between the various observed pathological types. Detailed weights and percentages can be found in Table 2.
in that study no mention was made about ASCs, on the contrary, in our study, we found that for SQCC patients, non-smokers were more at risk. Worthy of mention is the high frequency of LUADs, SQCCs, and LCCs among non-smokers In China, we were able to outline eight pathological types during our study with LUADs proving to be the most prevalent pathological presentation in our cohort, Figure 7. There was also notable risk association between smoking and incidences of ASCs and SCCs. These and the gender discriminations of lung cancer pathologies will be subject of further study.

CONCLUSION

Lung cancer-associated genetic mutations are widespread in China. Detection is facilitated by the availability of screening centers in various hospitals including the hospitals where our study population was sampled. EGFR is one of the most prevalent genetic alterations among lung cancer patients, even though other genetic aberrations also exist. EGFR, ALK, HER2, and MET anomalies were more prevalent among females while KRAS, HRAS, BRAF, PIK3CA, CTNNB1, and other genes were more prevalent in males. Genetic mutations such as EGFR, KRAS, ALK, PIK3CA, HRAS, HER2, CTNNB1, BRAF, MET are more common in female non-smokers, with some mutations existing in non-smoking patients. ALK, KRAS, and BRAF genes anomalies were predominantly found among patients younger than 60 years, while the other genes in our study were predominant among older patients or showed no significant age bias. Subsequent to this expose detailing the peculiarities of Chinese patients’ genetic affiliations to lung cancer, more work needs to be done in collecting more detailed smoking histories to further increase the accuracy for future work.

REFERENCES

1. Couraud S, Barlesi F, Fontaine-Deraluelle C, Debieux D, Merlio J, Moreau L, et al. Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French cooperative thoracic intergroup biomarkers france study. Eur J Cancer. (2019) 116:86–97. doi: 10.1016/j.ejca.2019.04.016
2. Yun Y, Back J, Ghang H, Lee S, Kim Y, Lee S, et al. Hazard ratio of smoking on lung cancer in Korea according to histological type and gender. Lung. (2015) 194:281–9. doi: 10.1007/s00408-015-9836-1
3. Feng H, Wang X, Zhang Z, Tang C, Ye H, Jones L, et al. Identification of genetic mutations in human lung cancer by targeted sequencing. Cancer Inform. (2015) 14:CIN.S22941. doi: 10.4137/CIN.S22941
4. Powell H, Iyen-Omofoman B, Hubbard R, Baldwin D, Tata L. The association between smoking quantity and lung cancer in men and women. Chest. (2013) 143:123–9. doi: 10.1378/chest.12-1068
5. Tao A, Tang X, Sabloff B, Xiao L, Shigematsu H, Roth J, et al. Clinopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. J Thor Oncol. (2006) 1:231–9. doi: 10.1016/S1556-0864(15)31573-2
6. Suzuki M, Shiraishi K, Yoshida A, Shimada Y, Suzuki K, Asamura H, et al. HER2 gene mutations in non-small cell lung carcinomas: concurrence with her2 gene amplification and her2 protein expression and phosphorylation. Lung Cancer. (2015) 87:14–22. doi: 10.1016/j.lungcan.2014.10.014
7. Shammas M, Telomeres, lifestyle, cancer, and aging. Car Opin Clin Nutr Met Care. (2011) 14:28–34. doi: 10.1097/MCO.0b013e32834121b1

DATA AVAILABILITY STATEMENT

The datasets generated for this study are available on request to the corresponding author.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Scientific Research Committee of Beijing Shijitan Hospital. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

IA: writing—original draft, writing—review and editing, and visualization. XX: conceptualization, methodology, and supervision. JF, LH, JG, ZD, and JH: data curation and formal analysis. HD, TJ, and JW: project administration. XZ and MM: formal analysis and validation. XM: funding acquisition. HW, LP, and DL: resources. RG, ZX, DZ, CQ, and YM: data curation and formal analysis. HM: supervision. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by National Natural Science Fund Youth Project (81700007), Research and Innovation fund of the Ministry of Education (2018A03026), Beijing Natural Science Foundation (2019A10), “Qingmiao” plan of Beijing Municipal Hospital Administration (2018QJM4), Outstanding top talent (2019YXBJ1), Capital Health Development Scientific Research Unit matching fund (2020-2Z-2086), and Excellent talents in Beijing “Youth top team” (2019YXBJ2).

REFERENCES

1. Couraud S, Barlesi F, Fontaine-Deraluelle C, Debieux D, Merlio J, Moreau L, et al. Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French cooperative thoracic intergroup biomarkers France study. Eur J Cancer. (2019) 116:86–97. doi: 10.1016/j.ejca.2019.04.016
2. Yun Y, Back J, Ghang H, Lee S, Kim Y, Lee S, et al. Hazard ratio of smoking on lung cancer in Korea according to histological type and gender. Lung. (2015) 194:281–9. doi: 10.1007/s00408-015-9836-1
3. Feng H, Wang X, Zhang Z, Tang C, Ye H, Jones L, et al. Identification of genetic mutations in human lung cancer by targeted sequencing. Cancer Inform. (2015) 14:CIN.S22941. doi: 10.4137/CIN.S22941
4. Powell H, Iyen-Omofoman B, Hubbard R, Baldwin D, Tata L. The association between smoking quantity and lung cancer in men and women. Chest. (2013) 143:123–9. doi: 10.1378/chest.12-1068
5. Tao A, Tang X, Sabloff B, Xiao L, Shigematsu H, Roth J, et al. Clinopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. J Thor Oncol. (2006) 1:231–9. doi: 10.1016/S1556-0864(15)31573-2
6. Suzuki M, Shiraishi K, Yoshida A, Shimada Y, Suzuki K, Asamura H, et al. HER2 gene mutations in non-small cell lung carcinomas: concurrence with her2 gene amplification and her2 protein expression and phosphorylation. Lung Cancer. (2015) 87:14–22. doi: 10.1016/j.lungcan.2014.10.014
7. Shammas M, Telomeres, lifestyle, cancer, and aging. Car Opin Clin Nutr Met Care. (2011) 14:28–34. doi: 10.1097/MCO.0b013e32834121b1

8. Dearden S, Stevens J, Wu Y, Blowers D. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol. (2013) 24:2371–6. doi: 10.1093/annonc/mdt205
9. Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saji N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. (2009) 361:947–57. doi: 10.1056/NEJMoa0810699
10. Gogli L, Schellfer M, Michaela I, Michels S, Fischer R, Serke M, et al. Clinical and molecular characteristics of non-small cell lung cancer in patients harboring CTNNB1 mutations. J Clin Oncol. (2015) 33(15_suppl):8098. doi: 10.1200/jco.2015.33.15_suppl.8098
11. Girard N. Optimizing outcomes inEGFRTKmutation-positive NSCLC: which tyrosine kinase inhibitor and when? Future Oncol. (2018) 14:1117–32. doi: 10.2217/fon-2017-0636
12. Girard N, Sima C, Jackman D, Sequist L, Chen H, Yang J, et al. Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma. Eur Respir J. (2011) 39:366–72. doi: 10.1183/09031936.0010111
13. Kaiser J, Heidenreich W, Monchaux G, Morlier J, Collier C. Lung tumour risk in radon-exposed rats from different experiments: comparative analysis with biologically based models. Radiat Environ Biophys. (2004) 43:189–201. doi: 10.1007/s00411-004-0251-x
14. Kim H, Shim H, Chung J, Lee Y, Hong Y, Rha S, et al. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Cancer. (2011) 118:729–39. doi: 10.1002/cncr.26311
15. Gorukmez O, Yakut T, Gorukmez O, Sag S, Karkacak M, Kanat O. Distribution of KRAS and BRAF mutations in metastatic colorectal
cancers in turkish patients. *Asian Pacific J Cancer Prev.* (2016) 17:1175–9. doi: 10.7314/APJCP.2016.17.3.1175

16. Kodaz H. Frequency of RAS Mutations (KRAS, NRAS, HRAS) in human solid cancer. *Eur J Med Oncol.* (2017) 1:1–7. doi: 10.14744/ejmo.2017.2293

17. Kobayashi M, Sonobe T, Takahashi T, Yoshizawa A, Ishikawa M, Kikuchi R, et al. Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer. *Anticancer Research.* (2011) 31:4619–23.

18. Schabath M, Cress W, Muñoz-Antonia T. Racial and ethnic differences in the epidemiology and genomics of lung cancer. *Cancer Control.* (2016) 23:338–46. doi: 10.1177/10737488162300405

19. Shaw A, Yeap B, Mino-Kenudson M, Digumarthy S, Costa D, Heist R, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. *J Clin Oncol.* (2009) 27:4247–53. doi: 10.1200/JCO.2009.22.6993

20. Chen J, Yang H, Aabo A, Amer L, Sherbaf F, Tan C, et al. Genomic landscape of lung adenocarcinoma in East Asians. *Nat Genet.* (2020) 52:177–86. doi: 10.1038/s41588-019-0569-6

21. Martelli M, Sozzi G, Hernandez L, Pettirossi V, Navarro A, Conte D, et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. *Am J Pathol.* (2009) 174:661–70. doi: 10.2335/apath.2009.080755

22. Alberg A, Brock M, Ford J, Samet J, Spivack S. Epidemiology of lung cancer. *Am J Epidemiol.* (2005) 162:317–21. doi: 10.1093/aje/kwi144

23. Sakurada A, Shepherd F, Tsao M. Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: impact of primary or secondary mutations. *Arch Pathol Lab Med.* (2001) 125:1979–89. doi: 10.1007/s00262-009-0677-8

24. Koivunen J, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes A, et al. Characterization of the transforming EML4-ALK fusion gene in non-small cell lung cancer who harbor EML4-ALK. *J Clin Oncol.* (2013) 31:4619–23. doi: 10.1200/JCO.2012.42.9829

25. Graham R, Treece A, Lindeman N, Vasalos P, Shan, M, Jennings LJ, et al. Worldwide frequency of commonly detected EGFR mutations. *Arch Pathol Lab Med.* (2018) 142:163–7. doi: 10.1001/sj.arpa.2016.0579-CP

26. Hsieh R, Lim K, Kuo H, Tzen C, Huang M. Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer. *Chest.* (2005) 128:317–21. doi: 10.1378/chest.128.1.317

27. Sakurada A, Shepherd F, Tsao M. Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: impact of primary or secondary mutations. *Clin Lung Cancer.* (2009) 7:S138–S44. doi: 10.3816/CLC.2006a.005

28. Lustgarten J. Cancer, aging and immunotherapy: lessons learned from animal models. *Cancer Immunol Immunother.* (2009) 58:1979–89. doi: 10.1007/s00262-009-0677-8

29. Riely G, Binder A, Jänne P. New targetable oncogenes in non-small-cell lung cancer. *J Clin Oncol.* (2013) 31:1097–104. doi: 10.1200/JCO.2012.42.9829

30. Tomizawa K, Suda K, Onozato R, Kosaka T, Endoh H, Sekido Y, et al. Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers. *Lung Cancer.* (2011) 74:139–44. doi: 10.1016/j.lungcan.2011.01.014

31. Shigemitsu K, Sekido Y, Usami N, Mori S, Sato M, Horio Y, et al. Genetic alteration of the β-catenin gene (CTNNB1) in human lung cancer and malignant mesothelioma and identification of a new 3p21.3 homozygous deletion. *Oncogene.* (2001) 20:4249–57. doi: 10.1038/sj.00313-1204557

32. Li Y, Li Y, Yang T, Wei S, Wang J, Wang M, et al. Clinical significance of EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. *Cancer Control.* (2008) 14:4275–83. doi: 10.1158/1078-0432.CCR-08-0168

33. Tomizawa K, Suda K, Onozato R, Kosaka T, Endoh H, Sekido Y, et al. Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers. *Lung Cancer.* (2011) 74:139–44. doi: 10.1016/j.lungcan.2011.01.014

34. Tseng C, Chiang C, Tseng J, Yang T, Hsu K, Chen K, et al. EGFR mutation, KRAS mutation, and histologic subtype predict EGFR mutations in non-small cell lung cancer. *PLoS ONE.* (2012) 8:e52093. doi: 10.1371/journal.pone.0052093

35. Shigemitsu K, Sekido Y, Usami N, Mori S, Sato M, Horio Y, et al. Genetic alteration of the β-catenin gene (CTNNB1) in human lung cancer and malignant mesothelioma and identification of a new 3p21.3 homozygous deletion. *Oncogene.* (2001) 20:4249–57. doi: 10.1038/sj.00313-1204557

36. Li Y, Li Y, Yang T, Wei S, Wang J, Wang M, et al. Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 chinese patients with non-small cell lung cancer. *PLoS ONE.* (2013) 8:e52093. doi: 10.1371/journal.pone.0052093

37. Brooks-Wilson A. Genetics of healthy aging and longevity. *Hum Genet.* (2001) 20:4249–57. doi: 10.1038/sj.00313-1204557

38. Thun M, Carter B, Feskanich D, Freedman N, Prentice R, Lopez A, et al. 50-year trends in smoking-related mortality in the United States. *N Engl J Med.* (2013) 368:351–64. doi: 10.1056/NEJMc1211127

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.